| |
DDW/2015: High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir,
Dasabuvir, and Ribavirin in Patients With Cirrhosis: Data From the TURQUOISE-II Study
|
| |
| |
Reported by Jules Levin
DDW 2015 - Digestive Disease Week, May 17-19, 2015, Washington, DC
Stanislas Pol1, Pietro Andreone2, Sam Lee3, Stefan Bourgeois4, Yuanyuan Tang5, Roger Trinh5, Marisol Marti nez5, Paul J Pockros6
1Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 2University of Bologna, Bologna, Italy; 3University of Calgary, Calgary, Alberta, Canada; 4ZNA Stuivenberg, Antwerpen, Belgium; 5AbbVie Inc., North Chicago, Illinois, United States; 6Scripps Clinic, La Jolla, California, United States
EASL: Abbvie at EASL 2015 - Healthcare Economics, Clinical Trials - (05/11/15)
EASL: Adherence to Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II Trials - (05/18/15)
EASL: PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR, DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES - (05/18/15)
EASL: Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection - (05/18/15)
EASL - The International Liver Congress 2015 50th Annual Meeting of the European
Association for the Study of the Liver Vienna, Austria April 22-26
|
|
| |
| |
|
|
|
